B细胞受体通路抑制剂在慢性淋巴细胞白血病治疗中的研究进展：第57届美国血液学会年会报道

随着Bruton酪氨酸激酶（BTK）抑制剂依鲁替尼（ibrutinib）及磷脂酰肌醇-3-激酶（PI3K）抑制剂idelalisib在复发／难治非霍奇金淋巴瘤（NHL）治疗中的成功，一系列新的B细胞受体（BCR）通路抑制剂也逐步进入临床试验。第57届美国血液学会（ASH）年会继续对依鲁替尼和idelalisib单药或联合用药治疗慢性淋巴细胞白血病（CLL）的探索保持了高度热情。另外脾酪氨酸激酶（SYK）抑制剂及新的BTK和PI3K抑制剂也崭露头角，为改善依鲁替尼和idelalisib耐药患者的疗效提供了新的选择。文章就第57届ASH年会中关于BCR通路抑制剂治疗CLL的进展进行介绍。

Research progress of B cell receptor pathway inhibitors in the treatment of chronic lymphocytic leukemia:reports from the 57th American Society of Hematology annual meeting

With the recent success of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, and the phosphoinositide-3-kinase (PI3K) inhibitor idelalisib in the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL), a number of new agents targeting the B cell receptor (BCR) pathway are in clinical development. In the 57th American Society of Hematology (ASH) annual meeting, great interests are still focused on these two drugs, either monotherapy or combination in the treatment of CLL. On the other hand, SYK inhibitors, new BTK and PI3K antagonists are also coming to the forefront, casting a new light on the treatment of ibrutinib/idelalisb-resistant patients. The progresses of BCR pathway inhibitors in CLL will be summarized in this paper based on the reports in the 57th ASH annual meeting.